Masimo has made a groundbreaking entry into the healthcare market by securing the first Food and Drug Administration (FDA) approval for an over-the-counter (OTC) medical fingertip pulse oximeter. This notable achievement with the Mightysat device, which is priced at approximately $300, distinguishes it from the plethora of non-FDA-cleared consumer pulse oximeters available in drugstores and online. This milestone underscores Masimo’s dedication to offering consumers dependable and officially sanctioned health monitoring devices.
The FDA’s endorsement of Mightysat through a 510(k) clearance, recognizing its substantial similarity to a previously released prescription Masimo product from 2019, signals the FDA’s acknowledgment of the necessity for OTC devices that meet medical standards. This approval follows the FDA’s 2022 pulse oximeter evaluation, revealing a significant gap in the market for FDA-cleared OTC options. Pulse oximeter Mightysat is set to bridge this void by providing a tool capable of delivering precise measurements of oxygen saturation and pulse rates, addressing a notable deficiency among the vast array of wellness and hobbyist products available.
Mightysat sets a new benchmark by integrating Masimo SET pulse oximetry technology, known for its use in Masimo’s prescription devices, yet now reconfigured for consumer applications. Masimo has made specific adjustments, such as removing the capability to monitor respiration rate and Pleth Variability Index and updating the calibration curve for better performance across various skin pigments and genders. These changes ensure that Mightysat caters to the home user’s distinct needs. The device’s calibration improvements, validated through bench testing in low perfusion scenarios, aim to mitigate FDA-expressed concerns regarding the influence of skin pigmentation and circulation on the accuracy of readings.
Pioneering Accessible Medical Technology with OTC Medical Fingertip Pulse Oximeter
Masimo’s launch of Mightysat on its website, with plans for its availability in retail and drug stores nationwide, signifies an ambitious expansion into the consumer health sector. This move is part of Masimo’s strategic push into the consumer marketplace, further exemplified by the introduction of its Stork baby monitor and the projected growth of its retail footprint, facilitated by the acquisition of Sound United in 2022.
Masimo’s venture into the OTC market with Mightysat not only fulfills a previously unmet need for medically reliable pulse oximetry options for consumers but also paves the way for future innovations in home-based health monitoring. This development represents a significant stride towards enhancing the accessibility and reliability of health monitoring technology for consumers, reinforcing Masimo’s role as a pioneer in healthcare innovation.
Resource: Medtechdive, February 14, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
